A composition comprises or consists essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). Preferably, the composition further comprises at least one non-cannabinoid component of cannabis, in particular, one or more terpenes and/or one or more cannabichromene type compounds, in particular cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). Preferably, the composition is absent or substantially absent of other cannabinoids, in particular, tetrahydrocannabivarin (THCV) and/or tetrahydrocannbinol (THC). Preferably, the cannabidivarin (CBDV) and cannabidiol (CBD) are present in a ratio of from 7:1 to 1:2 (CBDV:CBD). An extract or botanical drug substance comprising the phytocannabinoids CBDV and CBD but substantially absent of the cannabinoids THCV and THC is also provided. A combination of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) for use in the treatment of neurological conditions, characterised by hyper-excitability of the central nervous system such as epilepsy, convulsions and seizures is also outlined.
